RxDoctor Payments Data

Leslie Boyd, MD

Gynecologic Oncology · New York, NYNPI 1497967079

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,470 of the $1,628 with a category attached, or 90.3%. AstraZeneca accounts for 94.6% of it on its own, with 2 other manufacturers making up the rest.

$1,628in general payments, 2019–2025

Across 4 payments — averaging $406.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Viiv Healthcare Company$64
  • Medtronic$24
$281,121in research payments, 2019–2025

Across 19 payments — averaging $14,796 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$164K
  • Seagen Inc.$118K

What the payments were for

  • Consulting fees$1,47090%
  • Food & beverage$15810%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$1,539
Viiv Healthcare Company1$64
Medtronic1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,628 in reported general payments places this provider in the 60th percentile of 154 gynecologic oncology providers in New York.

See all gynecologic oncology providers in New York

Medicare billing

Part B allowed, 2024
$84,392
Medicare patients
165
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →